Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meeting.

[1]  S. Pennington,et al.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs , 2018, Clinical Reviews in Allergy & Immunology.

[2]  G. Shaddick,et al.  Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort , 2017, Rheumatology.

[3]  Y. Narisawa,et al.  Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients , 2017, The Journal of dermatology.

[4]  E. Diamandis,et al.  Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery , 2017, Critical reviews in clinical laboratory sciences.

[5]  Gavin Shaddick,et al.  Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study , 2017, Annals of the rheumatic diseases.

[6]  A. Lim,et al.  Microflow imaging: New Doppler technology to detect low-grade inflammation in patients with arthritis , 2017, European Radiology.

[7]  A. Barton,et al.  Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis , 2017, Annals of the rheumatic diseases.

[8]  P. Giannoudis,et al.  Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis , 2017, Arthritis & rheumatology.

[9]  S. Feldman,et al.  Real‐world burden of comorbidities in US patients with psoriasis , 2017, Journal of the American Academy of Dermatology.

[10]  Birgit Schilling,et al.  Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques , 2017, Expert review of proteomics.

[11]  M. D. de Wit,et al.  A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis , 2017, The Journal of Rheumatology.

[12]  W. Tillett,et al.  Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study , 2017, The Patient - Patient-Centered Outcomes Research.

[13]  R. Landewé,et al.  Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort , 2017, RMD Open.

[14]  J. Braun,et al.  Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years , 2016, The Journal of Rheumatology.

[15]  Ruedi Aebersold,et al.  Mass-spectrometric exploration of proteome structure and function , 2016, Nature.

[16]  K. Michaud,et al.  Changes in Body Mass Related to the Initiation of Disease‐Modifying Therapies in Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[17]  A. Ogdie,et al.  Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis , 2016, Annals of the rheumatic diseases.

[18]  D. Gladman,et al.  Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis , 2016, Arthritis & rheumatology.

[19]  Andrew J. Percy,et al.  Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential , 2016, Expert review of proteomics.

[20]  M. Dunn,et al.  A clinically based protein discovery strategy to identify potential biomarkers of response to anti‐TNF‐α treatment of psoriatic arthritis , 2016, Proteomics. Clinical applications.

[21]  S. Rajagopalan,et al.  Phosphodiesterase‐4 inhibition as a therapeutic strategy for metabolic disorders , 2016, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[22]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[23]  D. Gladman,et al.  The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study , 2016, Arthritis & rheumatology.

[24]  J. Bowes,et al.  Replication of a distinct psoriatic arthritis risk variant at the IL23R locus , 2016, Annals of the rheumatic diseases.

[25]  Søren Brunak,et al.  Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci , 2016, Nature Genetics.

[26]  O. FitzGerald,et al.  Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions , 2016, The Journal of Rheumatology.

[27]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[28]  Dennis McGonagle,et al.  'MHC-I-opathy'—unified concept for spondyloarthritis and Behçet disease , 2015, Nature Reviews Rheumatology.

[29]  C. Kwoh,et al.  High-Resolution US of Rheumatologic Diseases. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[30]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 , 2015 .

[31]  H. Doll,et al.  Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? , 2015, Rheumatology.

[32]  C. Roux,et al.  Ultrasound study of entheses in psoriasis patients with or without musculoskeletal symptoms: A prospective study. , 2015, Joint, bone, spine : revue du rhumatisme.

[33]  A. Janež,et al.  Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study , 2015, Journal of Ovarian Research.

[34]  O. FitzGerald,et al.  Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. , 2015, Annals of the rheumatic diseases.

[35]  S. Pennington,et al.  Early biomarkers of joint damage in rheumatoid and psoriatic arthritis , 2015, Arthritis Research & Therapy.

[36]  John D Reveille,et al.  Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1 , 2015, Nature Communications.

[37]  S. Pennington,et al.  Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management , 2015, Current Rheumatology Reports.

[38]  C. Wallace,et al.  Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis , 2015, Nature Communications.

[39]  D. Gladman,et al.  Gene expression differences between psoriasis patients with and without inflammatory arthritis. , 2015, The Journal of investigative dermatology.

[40]  E. Diamandis,et al.  Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers , 2015, Clinical Proteomics.

[41]  Vinod Chandran,et al.  Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers , 2015, Clinical Proteomics.

[42]  F. Buicu,et al.  Prevalence of Metabolic Syndrome in Psoriatic Arthritis and Rheumatoid Arthritis , 2014 .

[43]  J. Reveille,et al.  Role of Protein Phosphatase Magnesium‐Dependent 1A and Anti–Protein Phosphatase Magnesium‐Dependent 1A Autoantibodies in Ankylosing Spondylitis , 2014, Arthritis & rheumatology.

[44]  R. Winchester,et al.  Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype , 2014, Annals of the rheumatic diseases.

[45]  P. Tak,et al.  Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis , 2014, Annals of the rheumatic diseases.

[46]  Vinod Chandran,et al.  Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes , 2014, American journal of human genetics.

[47]  O. FitzGerald,et al.  High Prevalence of Metabolic Syndrome and of Insulin Resistance in Psoriatic Arthritis is Associated with the Severity of Underlying Disease , 2014, The Journal of Rheumatology.

[48]  H. Forsblad-d’Elia,et al.  Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and Osteoporosis , 2014, The Journal of Rheumatology.

[49]  R. Queiró,et al.  Age at disease onset: a key factor for understanding psoriatic disease. , 2014, Rheumatology.

[50]  A. Jobling,et al.  AB0735 Diagnostic Delay Worsens Mobility and Work Disability in Ankylosing Spondylitis , 2014 .

[51]  J. Reveille.  An update on the contribution of the MHC to as susceptibility , 2014, Clinical Rheumatology.

[52]  D. Gladman,et al.  Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls? , 2014, The Journal of Rheumatology.

[53]  S. Targan,et al.  Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study , 2013, Arthritis Research & Therapy.

[54]  J. Reveille,et al.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.

[55]  M. D. Di Minno,et al.  Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers , 2013, Annals of the rheumatic diseases.

[56]  Peter Donnelly,et al.  Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci , 2013, Nature Genetics.

[57]  D. Gladman,et al.  Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis , 2013, Annals of the rheumatic diseases.

[58]  J. Carulli,et al.  Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis , 2013, PloS one.

[59]  G. Di Minno,et al.  Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis , 2013, Arthritis care & research.

[60]  P. Emery,et al.  Ultrasonographic Assessment of Nail in Psoriatic Disease Shows a Link between Onychopathy and Distal Interphalangeal Joint Extensor Tendon Enthesopathy , 2012, Dermatology.

[61]  S. Pennington,et al.  New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis , 2012, Arthritis Research & Therapy.

[62]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[63]  J. Gudjonsson,et al.  Psoriatic Arthritis and Onycholysis — Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study , 2012, The Journal of Rheumatology.

[64]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[65]  K. Rabe,et al.  Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[66]  A. Qureshi,et al.  Obesity and risk of incident psoriatic arthritis in US women , 2012, Annals of the rheumatic diseases.

[67]  A. Ogdie,et al.  Obesity and the risk of psoriatic arthritis: a population-based study , 2012, Annals of the rheumatic diseases.

[68]  P. Gisondi,et al.  Preliminary Evidence That Subclinical Enthesopathy May Predict Psoriatic Arthritis in Patients with Psoriasis , 2011, The Journal of Rheumatology.

[69]  C. Acebes,et al.  High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. , 2011, Rheumatology.

[70]  D. Gladman,et al.  Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis , 2011, Arthritis care & research.

[71]  S. Chimenti,et al.  Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti‐TNF‐α treatment , 2011, Dermatologic therapy.

[72]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[73]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[74]  B. Leung,et al.  Serum Monocyte Chemotactic Protein-1 Concentrations Distinguish Patients With Ankylosing Spondylitis From Patients With Mechanical Low Back Pain , 2011, Journal of spinal disorders & techniques.

[75]  Fraser Cummings,et al.  Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis , 2011, The Journal of Immunology.

[76]  D. Ye,et al.  Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis , 2011, Clinical Rheumatology.

[77]  Christian Gieger,et al.  Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.

[78]  J. Gu,et al.  Pathogenesis of ankylosing spondylitis , 2010, Nature Reviews Rheumatology.

[79]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[80]  A. Kárason,et al.  A strong heritability of psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study. , 2009, Rheumatology.

[81]  A. Malaviya,et al.  Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes—an Indian perspective , 2009, Clinical Rheumatology.

[82]  S. Gabriel,et al.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. , 2009, Arthritis and rheumatism.

[83]  D. Mcgonagle,et al.  The Importance of ‘Mechnikov’s Thorn’ for an Improved Understanding of 21st Century Medicine and Immunology: A View from the Eye , 2008, Scandinavian journal of immunology.

[84]  M. Benjamin,et al.  Histopathologic changes at "synovio-entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. , 2007, Arthritis and rheumatism.

[85]  A. Silman,et al.  Environmental risk factors for the development of psoriatic arthritis: results from a case–control study , 2007, Annals of the rheumatic diseases.

[86]  P. Gisondi,et al.  Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case–control study , 2007, Annals of the rheumatic diseases.

[87]  M. Benjamin,et al.  The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. , 2006, Rheumatology.

[88]  D Loreck,et al.  Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. , 1999, Arthritis and rheumatism.

[89]  P. Emery,et al.  Psoriatic arthritis: a unified concept twenty years on. , 1999, Arthritis and rheumatism.

[90]  M. Dougados,et al.  Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. , 1999, The Journal of rheumatology.

[91]  D. Gladman,et al.  Psoriatic Arthritis. , 2017, The New England journal of medicine.